GLP-1 generic drugs flood into the market, and the government strengthens supervision
NEW DELHI: With prices of GLP-1 drugs plummeting and generics flooding the market, the government has cracked down on misuse of such drugs, inspecting 49 companies and issuing notices, while also pointing out the risks of unsupervised consumption in a detailed advisory.To ensure ethical pharmaceutical practices, the Drug Controller General of India has intensified monitoring of unauthorized sale and promotion of medicines. In India, GLP-1 drugs can be prescribed only by endocrinologists, internal medicine specialists and cardiologists.Officials have expressed concerns about the growing on-demand supply from retail pharmacies, online platforms, wholesalers and health clinics. Inspections across the country revealed irregularities such as inappropriate prescriptions and misleading marketing. One recommendation instructs manufacturers to stop advertising for non-prescription uses, warning of license revocation, fines and legal action.GLP-1 drugs, used to treat type 2 diabetes and obesity, pose risks if abused. Side effects include vomiting, pancreatitis, kidney damage, and intestinal obstruction.
